FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma
C Esche, VM Subbotin, C Maliszewski, MT Lotze… - Cancer research, 1998 - AACR
C Esche, VM Subbotin, C Maliszewski, MT Lotze, MR Shurin
Cancer research, 1998•AACRSuccessful treatment of melanoma and lymphoma may result from the induction of specific
antitumor immunity. Dendritic cells (DCs) are powerful antigen-presenting cells and show a
remarkable capacity to stimulate antigen-specific T-cell responses. Administration of FLT3
ligand (FL) results in a reversible accumulation of functionally active DCs in both lymphoid
and nonlymphoid tissues. Therefore, we evaluated the possible antitumor effect of FL in
murine melanoma (B16 and CL8-1) and lymphoma (EL-4) models. In all experiments, tumor …
antitumor immunity. Dendritic cells (DCs) are powerful antigen-presenting cells and show a
remarkable capacity to stimulate antigen-specific T-cell responses. Administration of FLT3
ligand (FL) results in a reversible accumulation of functionally active DCs in both lymphoid
and nonlymphoid tissues. Therefore, we evaluated the possible antitumor effect of FL in
murine melanoma (B16 and CL8-1) and lymphoma (EL-4) models. In all experiments, tumor …
Abstract
Successful treatment of melanoma and lymphoma may result from the induction of specific antitumor immunity. Dendritic cells (DCs) are powerful antigen-presenting cells and show a remarkable capacity to stimulate antigen-specific T-cell responses. Administration of FLT3 ligand (FL) results in a reversible accumulation of functionally active DCs in both lymphoid and nonlymphoid tissues. Therefore, we evaluated the possible antitumor effect of FL in murine melanoma (B16 and CL8-1) and lymphoma (EL-4) models. In all experiments, tumor growth was significantly inhibited by FL administration. Analysis by immunohistochemistry revealed an increase in the DC accumulation within B16 and EL-4 tumors after treatment with FL. No change was observed for CL8-1 melanoma. These data suggest a potential role for FL in the immunotherapy of malignant skin tumors and possible DC involvement in this effect.
AACR